Cargando…

MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load

BACKGROUND: The sieve analysis for the Step trial found evidence that breakthrough HIV-1 sequences for MRKAd5/HIV-1 Gag/Pol/Nef vaccine recipients were more divergent from the vaccine insert than placebo sequences in regions with predicted epitopes. We linked the viral sequence data with immune resp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janes, Holly, Frahm, Nicole, DeCamp, Allan, Rolland, Morgane, Gabriel, Erin, Wolfson, Julian, Hertz, Tomer, Kallas, Esper, Goepfert, Paul, Friedrich, David P., Corey, Lawrence, Mullins, James I., McElrath, M. Juliana, Gilbert, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428369/ https://www.ncbi.nlm.nih.gov/pubmed/22952672 http://dx.doi.org/10.1371/journal.pone.0043396

Ejemplares similares

P08-06 LB. A genome-wide association study of host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the STEP trial
por: Fellay, J, et al.
Publicado: (2009)

HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins
por: Brumme, Zabrina L., et al.
Publicado: (2009)

Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses
por: Hopkins, Kathryn L., et al.
Publicado: (2014)

Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag–pol–nef antigen
por: Herath, S., et al.
Publicado: (2015)

P19-32. HIV-1 vaccine design based on human vaccine trials to improve Gag, Pol, Nef and Env specific immune responses
por: Wild, J, et al.
Publicado: (2009)

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults
por: Omosa-Manyonyi, Gloria, et al.
Publicado: (2015)

FRET analysis of HIV‐1 Gag and GagPol interactions
por: Takagi, Shimon, et al.
Publicado: (2017)

HIV Pol Inhibits HIV Budding and Mediates the Severe Budding Defect of Gag-Pol
por: Gan, Xin, et al.
Publicado: (2012)

Modulation of HIV-1 Gag/Gag-Pol frameshifting by tRNA abundance
por: Korniy, Natalia, et al.
Publicado: (2019)

Effects of reduced gag cleavage efficiency on HIV-1 Gag-Pol package
por: Lin, Yi-Ru, et al.
Publicado: (2022)

P19-47. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity
por: Gabitzsch, ES, et al.
Publicado: (2009)

HIV-1 Vaccine-Induced T-Cell Reponses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1
por: Hertz, Tomer, et al.
Publicado: (2013)

The recognition of HIV-1 consensus group M Gag and Nef peptide reagents in mono- and multi-clade epidemics: implications for HIV vaccine design
por: Zembe, L, et al.
Publicado: (2012)

Enhancement of ribosomal frameshifting by oligonucleotides targeted to the HIV gag-pol region.
por: Vickers, T A, et al.
Publicado: (1992)

Potent Nonnucleoside Reverse Transcriptase Inhibitors Target HIV-1 Gag-Pol
por: Figueiredo, Anna, et al.
Publicado: (2006)

HIV-1 Mutant Assembly, Processing and Infectivity Expresses Pol Independent of Gag
por: Yu, Fu-Hsien, et al.
Publicado: (2020)

Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials
por: Fiore-Gartland, Andrew, et al.
Publicado: (2016)

Enhancement of viral escape in HIV-1 Nef by STEP vaccination
por: Park, Sung Yong, et al.
Publicado: (2016)

Profiles of Human Serum Antibody Responses Elicited by Three Leading HIV Vaccines Focusing on the Induction of Env-Specific Antibodies
por: Vaine, Michael, et al.
Publicado: (2010)

HIV-1 Nef promotes the localization of Gag to the cell membrane and facilitates viral cell-to-cell transfer
por: Malbec, Marine, et al.
Publicado: (2013)

Lower Viral Loads and Slower CD4(+) T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02
por: Leitman, Ellen M., et al.
Publicado: (2016)

Characterization of HIV-1 gag and nef in Cameroon: further evidence of extreme diversity at the origin of the HIV-1 group M epidemic
por: Tongo, Marcel, et al.
Publicado: (2013)

COVID-19 vaccination and HIV-1 acquisition – Authors’ reply
por: Buchbinder, Susan P, et al.
Publicado: (2022)

Gag-Pol Processing during HIV-1 Virion Maturation: A Systems Biology Approach
por: Könnyű, Balázs, et al.
Publicado: (2013)

P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
por: Rolland, MM, et al.
Publicado: (2009)

Stimulation of antiviral cellular immune responses by therapeutic vaccination of HIV-1-infected patients with dendritic cells transfected with gag, tat, rev and nef mRNA
por: Van Gulck, Ellen, et al.
Publicado: (2011)

Vaccination with MVA/HIV induces differential recruitment of monocyte subsets into the circulation and monocyte-specific transcriptional programs
por: Andersen-Nissen, E, et al.
Publicado: (2012)

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study
por: Huang, Yunda, et al.
Publicado: (2014)

An Essential Role of INI1/hSNF5 Chromatin Remodeling Protein in HIV-1 Posttranscriptional Events and Gag/Gag-Pol Stability
por: La Porte, Annalena, et al.
Publicado: (2016)

A Large Extension to HIV-1 Gag, Like Pol, Has Negative Impacts on Virion Assembly
por: Haraguchi, Hiyori, et al.
Publicado: (2012)

Gag-Pol Transframe Domain p6* Is Essential for HIV-1 Protease-Mediated Virus Maturation
por: Yu, Fu-Hsien, et al.
Publicado: (2015)

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials
por: Fischinger, Stephanie, et al.
Publicado: (2021)

P20-18. Diversity of Gag and Nef immunodominant regions in Brazilian HIV-1 B and F1 subtypes
por: Côrtes, FH, et al.
Publicado: (2009)

Effect of ART on poly functional profile of CD8 responses to Gag and Nef antigen in HIV infected Indian individuals
por: Mendiratta, Sanjay, et al.
Publicado: (2014)

Breadth of CD8 T-cell mediated inhibition of replication of diverse HIV-1 transmitted-founder isolates correlates with the breadth of recognition within a comprehensive HIV-1 Gag, Nef, Env and Pol potential T-cell epitope (PTE) peptide set
por: Hayes, Peter, et al.
Publicado: (2021)

HIV-1 Nef: at the crossroads
por: Foster, John L, et al.
Publicado: (2008)

Comparison of HIV-1 nef and gag Variations and Host HLA Characteristics as Determinants of Disease Progression among HIV-1 Vertically Infected Kenyan Children
por: Saina, Matilda Chelimo, et al.
Publicado: (2015)

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults
por: Buchbinder, Susan P., et al.
Publicado: (2017)

P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
por: Self, S, et al.
Publicado: (2009)

Correction: A Large Extension to HIV-1 Gag, Like Pol, Has Negative Impacts on Virion Assembly
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gmafe41fns7rig9kervatn8kmk